IRIS
SALA, GIANLUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.750
AS - Asia 1.636
EU - Europa 1.597
SA - Sud America 244
AF - Africa 33
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.264
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.697
SG - Singapore 811
IT - Italia 492
CN - Cina 434
IE - Irlanda 297
BR - Brasile 214
SE - Svezia 196
DE - Germania 120
VN - Vietnam 113
UA - Ucraina 89
GB - Regno Unito 82
TR - Turchia 77
IN - India 75
FR - Francia 69
FI - Finlandia 55
RU - Federazione Russa 48
HK - Hong Kong 39
CA - Canada 33
PL - Polonia 28
AT - Austria 24
BE - Belgio 19
JP - Giappone 19
ZA - Sudafrica 19
NL - Olanda 17
ES - Italia 12
MX - Messico 12
AR - Argentina 11
CZ - Repubblica Ceca 11
KR - Corea 11
BD - Bangladesh 9
LT - Lituania 8
AE - Emirati Arabi Uniti 7
GR - Grecia 7
IQ - Iraq 6
CH - Svizzera 5
EC - Ecuador 5
EG - Egitto 4
IL - Israele 4
PK - Pakistan 4
PY - Paraguay 4
RS - Serbia 4
UZ - Uzbekistan 4
DZ - Algeria 3
ID - Indonesia 3
JM - Giamaica 3
LK - Sri Lanka 3
MY - Malesia 3
VE - Venezuela 3
AU - Australia 2
AZ - Azerbaigian 2
BB - Barbados 2
BG - Bulgaria 2
CL - Cile 2
DK - Danimarca 2
HU - Ungheria 2
KE - Kenya 2
MA - Marocco 2
PE - Perù 2
TN - Tunisia 2
TW - Taiwan 2
UY - Uruguay 2
AL - Albania 1
CO - Colombia 1
EU - Europa 1
GD - Grenada 1
GE - Georgia 1
HN - Honduras 1
HR - Croazia 1
IR - Iran 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LI - Liechtenstein 1
LU - Lussemburgo 1
MD - Moldavia 1
MK - Macedonia 1
NG - Nigeria 1
NI - Nicaragua 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
QA - Qatar 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 6.264
Salva come PNG Salva come JPEG
Città #
Singapore 563
Chandler 411
Dublin 294
Ashburn 223
Dallas 202
Jacksonville 178
Beijing 163
Princeton 114
The Dalles 108
Los Angeles 89
Santa Clara 88
Ann Arbor 85
Chieti 73
New York 63
Pescara 61
Altamura 52
Boardman 48
Munich 48
Nanjing 45
Dearborn 44
Hong Kong 37
Izmir 36
Dong Ket 35
Wilmington 34
Buffalo 32
Ho Chi Minh City 26
Redondo Beach 26
Warsaw 25
Tongling 23
Denver 22
Hefei 22
Southend 22
Houston 21
Brussels 19
São Paulo 19
Turku 19
Hanoi 18
Montreal 18
Seattle 18
Washington 18
Brooklyn 17
Tokyo 17
Cambridge 16
Lappeenranta 16
Rome 16
Stockholm 16
Johannesburg 15
Atlanta 14
Nuremberg 14
Phoenix 14
Milan 13
Nanchang 13
Orem 13
Poplar 13
Pune 13
Chennai 12
Collecorvino 12
Hebei 11
Frankfurt am Main 10
Helsinki 10
London 10
Mcallen 10
Norwalk 10
Seoul 10
Woodbridge 10
San Francisco 9
Vienna 9
Chicago 8
Manchester 8
Montesilvano 8
Shenyang 8
Castignano 7
Falls Church 7
Mexico City 7
Rio de Janeiro 7
Zhengzhou 7
Brasília 6
Brno 6
Fairfield 6
Kunming 6
L’Aquila 6
Moscow 6
Tianjin 6
Ankara 5
Belo Horizonte 5
Boston 5
Campinas 5
Cleveland 5
Da Nang 5
Dubai 5
Finale Ligure 5
Macerata 5
Mumbai 5
Olomouc 5
Salvador 5
Shijiazhuang 5
Vancouver 5
Buenos Aires 4
Camerino 4
Goiânia 4
Totale 3.976
Salva come PNG Salva come JPEG
Nome #
miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance 188
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma 148
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma 147
Cold atmospheric plasma activated media selectively affects human head and neck cancer cell lines 144
Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer 139
ABCC3 is a novel target for the treatment of pancreatic cancer 133
ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs) 132
BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages 132
ERBB3 BINDING ANTIBODY 127
LGALS3BP antibody-drug-conjugate and its use for the treatment of cancer 125
Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer 124
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma 122
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 122
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates 121
Repurposing a psychoactive drug for children with cancer: p27 Kip1-dependent inhibition of metastatic neuroblastomas by Prozac 121
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. 118
CAF-Derived IL6 and GM-CSF Cooperate to Induce M2-like TAMs–Letter 118
Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8(+) T cell number and tumour growth in pancreatic cancer 117
Development of an anti-BAG3 humanized antibody for treatment of pancreatic cancer 113
Humanized anti-bag3 antibodies 111
Therapeutic efficacy of the novel stimuli-sensitive nano-ferritins containing doxorubicin in a head and neck cancer model 109
BAG3 induces fibroblasts to release key cytokines involved in pancreatic cell migration 107
PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes 103
HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications 98
Targeting vesicular lgals3bp by an antibody-drug conjugate as novel therapeutic strategy for neuroblastoma 98
EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer 95
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target 93
Breast cancer in the era of integrating "Omics" approaches 93
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer 92
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools 91
The G-protein-coupled receptor kinase GRK4 mediates homologous desensitization of metabotropic glutamate receptor 1 91
Phospholipase Cgamma1 is required for metastasis development and progression 90
EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. 90
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. 90
HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies 89
GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine 89
The E27 β2-adrenergic receptor polymorphism reduces the risk of myocardial infarction in dyslipidemic young males 88
The role of phospholipase Cγ1 in breast cancer and its clinical significance 88
Engineered human nanoferritin bearing the drug genz-644282 for cancer therapy 86
Dual PDK1/aurora kinase a inhibitors reduce pancreatic cancer cell proliferation and colony formation 85
Antibody-drug conjugates: The new frontier of chemotherapy 84
Proteomic meta-analysis unveils new frontiers for biomarkers research in pancreatic carcinoma 81
Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma 81
The role of phosphoinositide 3-kinase C2α in insulin signaling 80
HER-3: Hub for escape mechanisms 79
Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma 77
Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines 77
Concerted BAG3 and SIRPα blockade impairs pancreatic tumor growth 77
High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors 76
Endosialin-binding antibody 75
EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors 73
Feedback inhibition by RALT controls signal output by the ErbB network 71
Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control 68
Effects of an ErbB-3 antibody, MP-RM-1, on tumor growth and ligand-dependent and -independent activation of ErbB-3/akt signaling 66
Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin 65
Negative regulation of receptor tyrosine kinase signals 65
LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth 64
A phosphoinositide 3-kinase/phospholipase cgamma1 pathway regulates fibroblast growth factor-induced capillary tube formation 64
P63 role in breast cancer 62
MYC regulates metabolism through vesicular transfer of glycolytic kinases 62
Visualizing Galectin-3 Binding Protein Expression with ImmunoPET 61
EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate 58
Role of BAG3 in cancer progression: A therapeutic opportunity 58
Human head and neck cancer cell lines response to cold atmospheric plasma activated media is affected by the chemistry of culture media 56
Widespread in vivo efficacy of The-0504: A conditionally-activatable nanoferritin for tumor-agnostic targeting of CD71-expressing cancers 56
LGALS3BP is a potential target of antibody-drug conjugates in oral squamous cell carcinoma 56
The mitotic checkpoint kinase BUB1 is a direct and actionable target of MYB in adenoid cystic carcinoma 50
USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancer 49
Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target 42
Therapeutic potential of antibody‐drug conjugate‐based therapy in head and neck cancer: A systematic review 41
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans 35
A first-in-class non-cytotoxic nanocarrier based on a recombinant human ferritin boosts targeted therapy, chemotherapy and immunotherapy 33
Galectin-3-binding protein is a risk factor for Diabetes, Metabolic Syndrome, and Inflammation. Cross-sectional and Longitudinal Results from the InCHIANTI study 30
Evaluation of Antibody-Drug Conjugate Performances Using a Novel HPLC-DAD Method for Tumor-Specific Detection of DM4 and S-Methyl-DM4 20
null 20
New analytical challenges in characterization of Antibody-Drug Conjugates 16
Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker 15
Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer 13
null 6
Totale 6.629
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.784
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.784
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021205 0 0 0 0 0 60 24 15 16 34 9 47
2021/2022333 15 2 5 62 18 12 13 23 29 20 28 106
2022/20231.065 94 175 71 124 92 176 49 89 129 12 38 16
2023/2024638 38 15 64 33 36 214 97 26 5 25 13 72
2024/20251.657 60 301 242 66 45 74 71 74 218 130 228 148
2025/20261.708 284 134 372 450 422 46 0 0 0 0 0 0
Totale 6.629